Does the use of statins improve outcomes in coronary artery bypass graft surgery?

Research output: Contribution to journalArticleOtherpeer-review

4 Citations (Scopus)

Abstract

Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are one of the most frequently prescribed medications throughout the world with beneficial effects that extend beyond their lipid-lowering activity. It has been suggested that statins may offer a simple and cost-effective strategy to reduce some of the complications that occur in association with coronary artery bypass graft (CABG) surgery. Limited existing randomized trial evidence in the setting of cardiac surgery suggests that statins may reduce the incidence of postoperative atrial fibrillation. However, any effect of statins on other outcomes is less clear. The clinical significance of specific statin agent and dose, acute statin withdrawal and the potential benefits associated with statin reloading remain important yet currently unresolved issues. Despite limited high-quality evidence, class I recommendations have been made that all patients undergoing coronary artery bypass graft surgery should receive statin therapy unless contraindicated.
Original languageEnglish
Pages (from-to)1285 - 1288
Number of pages4
JournalExpert Review of Cardiovascular Therapy
Volume13
Issue number12
DOIs
Publication statusPublished - 2015

Cite this